Share Buyback Programme

Venture Life Group PLC

20 August 2026

 

20 August 2026

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

Share Buyback Programme

Venture Life Group plc (AIM: VLG), a recognised leader in proactive healthy longevity, product innovation, development, and commercialisation within the global consumer healthcare sector, is pleased to announce the decision to extend its share buyback programme (the "Programme") which expired on 31 July 2026. To-date, the Company has repurchased 8,933,943 ordinary shares of 0.3 pence each in the Company ("Ordinary Shares") pursuant to the Programme for a consideration of approximately £6.0 million.

The Board maintains the view that Venture Life's Ordinary Shares are undervalued relative to the Group's strong fundamentals and growth potential. By undertaking the Programme, the Company aims to further enhance earnings per share and deliver greater value to its shareholders. The Programme will be funded from the Company's existing cash resources and is intended to reduce the Company's share capital.

Pursuant to the terms of the Programme and in accordance with the authority granted at the Company's last Annual General Meeting, the Company is seeking to repurchase up to 3,871,288 Ordinary Shares in the market over the course of the period from the date of this announcement until 29 September 2026 (the "Expiry Date").

Ordinary Share repurchases will be made pursuant to the buyback authority granted at the Company's last Annual General Meeting. The maximum price which may be paid by the Company per Ordinary Share pursuant to the Programme shall not be more than 5 per cent. above the average middle market quotations for an Ordinary Share (as derived from the London Stock Exchange AIM All-Share List) for the five business days immediately preceding the date on which such share is contracted to be purchased.

The Company has appointed Cavendish Capital Markets Limited ("Cavendish") to manage the Programme on its behalf on a broker-managed basis, with trading decisions taken independently of, and uninfluenced by, the Company. There is no certainty that the Programme will be completed and it may be paused at any time if deemed appropriate by Cavendish with respect to market conditions. The Programme will continue until the earlier of the repurchase of the maximum number of Ordinary Shares or the Expiry Date.

Venture Life intends to hold all of the repurchased Ordinary Shares as Treasury Shares.

The Company has determined that it will not rely on the safe harbour conditions for trading set out in Article 3(2) and Article 3(3) of the Commission Delegated Regulation (EU) 2016/1052 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018) given the limited liquidity in the Ordinary Shares and limitations that the conditions would impose on the number of Ordinary Shares that can be purchased and, as such, the Company may (a) purchase Ordinary Shares at a price higher than the higher of the price of the last independent trade and the highest current independent bid for an Ordinary Share, and (b) purchase on any trading day materially in excess of 25 per cent of the average daily volume in the 20 trading days preceding the date on which the purchase is carried out.

On 1 May 2026, it was announced that Slater Investments Ltd ("Slater") was interested in 35,048,497 Ordinary Shares, representing approximately 28.78 per cent. of the total Ordinary Shares (excluding Ordinary Shares held in treasury) in issue at the time of the announcement. Assuming the Programme is implemented in full and Slater has not undertaken any further dealings in the Company's Ordinary Shares since that announcement, Slater's interest in the total issued Ordinary Shares (excluding Ordinary Shares held in treasury) would increase to a maximum of 30.07 per cent.

The Panel on Takeovers and Mergers has confirmed that, pursuant to Rule 37.1 of the Takeover Code, Slater will not incur an obligation to make a mandatory offer pursuant to Rule 9 of the Takeover Code should its interest in the Company exceed 30 per cent. of the total issued Ordinary Shares (excluding Ordinary Shares held in treasury) or increase above 30 per cent. of the total issued Ordinary Shares (excluding Ordinary Shares held in treasury) (as applicable), in each case as a result of any Ordinary Share purchases conducted through the Programme. This announcement is being made without the consent of Slater.

As at 19 August 2026, the Company's total issued share capital consisted of 128,860,145 Ordinary Shares, with one voting right per share, including 8,427,443 Ordinary Shares held in treasury. Therefore, the total number of voting rights in the Group is 120,432,702.

For further information, please contact:

Venture Life Group PLC                                                                                                    [phone]

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer 

Cavendish Capital Markets Limited (Nomad and Broker)                                             [phone] 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales) 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK,  Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

END